Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study
Paul Kwo, Norman Gitlin, Ronald Nahass, David Bernstein, Kyle Etzkorn, Sergio Rojter, Eugene Schiff, Mitchell Davis, Peter Ruane, Ziad Younes, Ronald Kalmeijer, Rekha Sinha, Monika Peeters, Oliver Lenz, Bart Fevery, Guy De La Rosa, Jane Scott, James Witek – 22 January 2016 – Effective antiviral therapy is essential for achieving sustained virological response (SVR) in hepatitis C virus (HCV)‐infected patients.